Protalix Therapy Eliminates Ulcerative Colitis in a Third of Patients in Phase 2 Trial

Protalix Therapy Eliminates Ulcerative Colitis in a Third of Patients in Phase 2 Trial
Protalix BioTherapeutics’ ulcerative colitis therapy OPRX-106 eradicated the disease in a third of the first 14 patients participating in a Phase 2 clinical trial. Fifty-seven percent of the patients responded to the treatment in some way, Protalix added. Although scientists have made major advances in ulcerative colitis treatment, there is no cure for the inflammatory bowel disease. Ulcerative

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *